AbbVie Inc., FCFF calculation

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net earnings attributable to AbbVie Inc.	4,863)	11,836)	11,542)	4,616)	7,882)
Net earnings attributable to noncontrolling interest	10)	9)	7)	6)	—)
Net noncash charges	15,153)	13,192)	12,459)	12,860)	6,893)
Changes in operating assets and liabilities, net of acquisitions	2,813)	(94)	(1,231)	106)	(1,451)
Cash flows from operating activities	22,839)	24,943)	22,777)	17,588)	13,324)
Interest paid, net of portion capitalized, net of tax¹	1,926)	2,238)	2,411)	2,069)	1,649)
Acquisitions of property and equipment	(777)	(695)	(787)	(798)	(552)
Free cash flow to the firm (FCFF)	23,988)	26,486)	24,401)	18,859)	14,421)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

Download chart

Item	Description	The company
FCFF	Free cash flow to the firm is the cash flow available to the AbbVie Inc. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made.	AbbVie Inc. FCFF increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.

AbbVie Inc., interest paid, net of tax calculation

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR¹	22.00%	12.10%	11.10%	21.00%	8.10%
Interest Paid, Net of Tax
Interest paid, net of portion capitalized, before tax	2,469)	2,546)	2,712)	2,619)	1,794)
Less: Interest paid, net of portion capitalized, tax²	543)	308)	301)	550)	145)
Interest paid, net of portion capitalized, net of tax	1,926)	2,238)	2,411)	2,069)	1,649)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

² 2023 Calculation
Interest paid, net of portion capitalized, tax = Interest paid, net of portion capitalized × EITR
= 2,469 × 22.00% = 543

Download chart

AbbVie Inc., current EV/FCFF calculation, comparison to benchmarks

Selected Financial Data (US$ in millions)
Enterprise value (EV)	340,959)
Free cash flow to the firm (FCFF)	23,988)
Valuation Ratio
EV/FCFF	14.21
Benchmarks
EV/FCFF, Competitors¹
Amgen Inc.	21.69
Bristol-Myers Squibb Co.	10.56
Danaher Corp.	32.91
Eli Lilly & Co.	641.00
Gilead Sciences Inc.	15.58
Johnson & Johnson	18.86
Merck & Co. Inc.	29.07
Moderna Inc.	—
Pfizer Inc.	30.25
Regeneron Pharmaceuticals Inc.	18.68
Thermo Fisher Scientific Inc.	26.58
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences	26.74
EV/FCFF, Industry
Health Care	23.67

Based on: 10-K (reporting date: 2023-12-31).

¹ Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.

AbbVie Inc., historical EV/FCFF calculation, comparison to benchmarks

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in millions)
Enterprise value (EV)¹	357,064)	321,803)	321,636)	263,033)	167,265)
Free cash flow to the firm (FCFF)²	23,988)	26,486)	24,401)	18,859)	14,421)
Valuation Ratio
EV/FCFF³	14.89	12.15	13.18	13.95	11.60
Benchmarks
EV/FCFF, Competitors⁴
Amgen Inc.	22.22	16.01	15.82	14.51	16.05
Bristol-Myers Squibb Co.	9.14	13.87	10.52	11.63	23.39
Danaher Corp.	36.34	25.74	28.25	30.66	37.11
Eli Lilly & Co.	655.33	59.14	38.37	39.01	36.26
Gilead Sciences Inc.	13.41	13.58	8.42	13.60	9.78
Johnson & Johnson	19.30	23.80	21.25	20.75	19.31
Merck & Co. Inc.	37.84	19.09	23.27	34.12	20.46
Moderna Inc.	—	11.76	3.86	29.20	—
Pfizer Inc.	32.24	9.15	8.40	21.74	19.44
Regeneron Pharmaceuticals Inc.	23.99	17.96	9.81	25.74	19.54
Thermo Fisher Scientific Inc.	28.85	31.61	33.14	26.14	28.88
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences	28.47	17.82	15.03	20.02	19.33
EV/FCFF, Industry
Health Care	24.38	17.63	16.41	17.93	18.26

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

² See details »

³ 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 357,064 ÷ 23,988 = 14.89

⁴ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
EV/FCFF	Enterprise value to free cash flow to the firm is whole company valuation indicator.	AbbVie Inc. EV/FCFF ratio decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.

AbbVie Inc. (NYSE:ABBV)

Enterprise Value to FCFF (EV/FCFF)

Free Cash Flow to The Firm (FCFF)

Interest Paid, Net of Tax

Enterprise Value to FCFF Ratio, Current

Enterprise Value to FCFF Ratio, Historical